Hormone and Dosimetric Data
| Date | Thyroxine (μg/dL) | fT4 (ng/dL) | TSH (mU/L) | Tg (ng/mL) | TSI index | Body retention (fraction of activity) | Body dose (cGy) | Blood dose (cGy) | 131I treatment (GBq) | Other treatment |
|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | ||||||||||
| Jan-98 | 13.1 | <0.01 | >30,000 | 6.2 | 0.87 | 150 | 194 | 1.85 | Restart antithyroid drug* | |
| Apr-98 | 1.6 | 0.06 | 0.76 | 207 | 275 | 2.59 | Restart antithyroid drug* | |||
| Sep/Oct-98 | 0.7 | 11.1 | >30,000 | 0.77 | 309 | 3.15 | ||||
| Oct-98 | 13 | Begin thyroxine at 0.05 mg/d | ||||||||
| Nov-98 | 2.2 | |||||||||
| Jan-99 | 0.9 | 17.8 | 4 | 0.29 | 219 | 311 | 5.7 | Restart thyroxine at 0.1 mg/d | ||
| Apr-99 | 1.4 | 0.8 | 28,193 | |||||||
| Jul-99 | 0.4 | 48 | >30,000 | 0.58 | 344 | 416 | 4.81 | Restart thyroxine at 0.1 mg/d | ||
| Oct/Nov-99 | 1.3 | 1.8 | 12,120 | Change thyroxine to 0.125 mg/d | ||||||
| Jan-00 | 0.57 | 27,300 | 3.1 | Continue thyroxine | ||||||
| Mar/Apr-00 | 1.6 | 0.23 | 17,800 | Continue thyroxine | ||||||
| Patient 2 | ||||||||||
| Dec-97 | 6.7 | 18 | 4,800 | 0.58 | 144 | 222 | 2.2 | Begin thyroxine at 0.125 mg/d | ||
| Apr-98 | 0.9 | 480 | Continue thyroxine | |||||||
| Sep-98 | 7.6 | 8 | 1,310 | 0.39 | 202 | 4.6 | Restart thyroxine | |||
| Nov-98 | 1.6 | 21 | 110 | |||||||
| Feb-00 | 9.7 | 11.2 | 150 | Stop thyroxine | ||||||
| Mar-00 | 0.67 | 34 | 247 | 0.23 | 161 | 5.6 | Restart thyroxine at 0.137 mg/d | |||
| Apr-00 | 1 |
↵* Before treatments with 131I, antithyroid drug was stopped at least 1 wk and thyroxine for 6 wk.
fT4 = free thyroxine; Tg = thyroglobulin.
Reference ranges are 4.4–12.4 μg/dL for thyroxine, 0.7–1.79 ng/dL for fT4, 0.3–5.5 mU/L for TSH, and ≤1.3 for TSI.